keyword
MENU ▼
Read by QxMD icon Read
search

"Non-small cell lung cancer" AND gemcitabine

keyword
https://www.readbyqxmd.com/read/27913776/necitumumab-for-the-treatment-of-squamous-cell-non-small-cell-lung-cancer
#1
Jessica K Brinkmeyer, Donald C Moore
Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of all cases and is further subdivided into adenocarcinoma, squamous cell, and large cell carcinoma. Necitumumab (Portrazza™, Eli Lilly and Company) is an anti-epidermal growth factor receptor monoclonal antibody approved for the first-line treatment of squamous cell non-small cell lung cancer in combination with cisplatin and gemcitabine. The safety and efficacy of necitumumab has been evaluated in two-phase III clinical trials, one demonstrating a lack of efficacy in non-squamous non-small cell lung cancer and another demonstrating improvement in overall survival and progression-free survival in squamous cell non-small cell lung cancer...
December 2, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27908619/correlation-of-dna-repair-gene-polymorphisms-with-clinical-outcome-in-patients-with-locally-advanced-non-small-cell-lung-cancer-receiving-induction-chemotherapy-followed-by-surgery
#2
Mariacarmela Santarpia, Jose Luis Ramirez, Itziar de Aguirre, Pilar Garrido, Maria Pérez Cano, Cristina Queralt, Jose Luis Gonzalez-Larriba, Amelia Insa, Mariano Provencio, Dolores Isla, Carlos Camps, Remei Blanco, Teresa Moran, Rafael Rosell
OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. MATERIALS AND METHODS: A total of 109 patients with stage IIIA and IIIB NSCLC were prospectively genotyped to examine a potential association between XPD 312 (aspartic acid [Asp]/asparagine [Asn]), XPD 751 (lysine [Lys]/glutamine [Gln]), and RRM1 (-37 C/A) polymorphisms with response and survival...
November 9, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27901493/has-aidi-injection-the-attenuation-and-synergistic-efficacy-to-gemcitabine-and-cisplatin-in-non-small-cell-lung-cancer-a-meta-analysis-of-36-randomized-controlled-trials
#3
Zheng Xiao, Chengqiong Wang, Ling Chen, Xuemei Tang, Lianhong Li, Nana Li, Jing Li, Qihai Gong, Fushan Tang, Jihong Feng, Xiaofei Li
Gemcitabine and cisplatin is the first line chemotherapy for non-small cell lung cancer with high toxicity. Aidi injection is a cantharidin and astragalu-based Chinese herbs injection in China. Has Aidi injection attenuation and synergistic efficacy to GP in NSCLC? There is lack of strong evidence to prove it. To further reveal it, we systematically evaluated all related studies. We collected all studies about Aidi injection plus GP for NSCLC in Medline, Embase, Web of Science, CNKI, VIP, Wanfang Database, CBM, CCRCT, Chi-CTR, and US-clinical trials (established to June 2015)...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27893326/randomized-prospective-biomarker-trial-of-ercc1-for-comparing-platinum-and-nonplatinum-therapy-in-advanced-non-small-cell-lung-cancer-ercc1-trial-et
#4
Siow Ming Lee, Mary Falzon, Fiona Blackhall, James Spicer, Marianne Nicolson, Abhro Chaudhuri, Gary Middleton, Samreen Ahmed, Jonathan Hicks, Barbara Crosse, Mark Napier, Julian M Singer, David Ferry, Conrad Lewanski, Martin Forster, Sally-Ann Rolls, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, Allan Hackshaw
Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC). We conducted the first randomized trial, to our knowledge, to evaluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive NSCLC as well as noninferiority for ERCC1-negative NSCLC. Patients and Methods This trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a randomization stratification factor...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27873136/afatinib-a-review-in-advanced-non-small-cell-lung-cancer
#5
REVIEW
Gillian M Keating
Afatinib (Giotrif(®), Gilotrif(®)) is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. In the first-line treatment of patients with advanced lung adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutations, afatinib significantly prolonged progression-free survival (PFS) and time to treatment failure (TTF), but not overall survival (OS), compared with gefitinib (LUX-Lung 7 trial). In the overall population of patients receiving first-line treatment for advanced lung adenocarcinoma with activating EGFR mutations, afatinib significantly prolonged PFS, but not OS, compared with pemetrexed plus cisplatin (LUX-Lung 3 trial) or gemcitabine plus cisplatin (LUX-Lung 6 trial)...
November 22, 2016: Targeted Oncology
https://www.readbyqxmd.com/read/27867559/impact-of-anticancer-drugs-price-cut-on-physician-s-prescription-choices-on-first-line-chemotherapy-regimens-and-health-expenditure-for-advanced-non-small-cell-lung-cancer-in-china
#6
Bei Li, Mei-Ying Li, Luan-Luan Sun, Jian Wang, Yan-Qing Zheng, Jing Hao
BACKGROUND: Increases in insurance coverage and price cut of drugs are two important measures to make health care more accessible and affordable. As far as we know, this was the first study to explore the impact of anticancer drug price cut on health expenses and oncologist's prescription decisions in China. METHODS: The 511 non-small cell lung cancer (NSCLC) patients were recruited from Qilu Affiliated Hospital of Shandong University from January 1, 2003 to December 31, 2010...
October 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27853379/fas-and-fasl-genetic-polymorphisms-impact-on-clinical-outcome-of-malignant-pleural-mesothelioma
#7
Manal El-Hamamsy, Ramy R Ghali, Amr S Saad, Sara M Shaheen, Ahmed M Salem
BACKGROUND: FAS-670 A>G (rs1800682) and FASL-844 C>T (rs763110) polymorphisms have been previously correlated with clinical outcome of non-small cell lung cancer (NSCLC) and breast and bladder cancers. We investigated the influence of these polymorphisms on clinical outcome of malignant pleural mesothelioma (MPM) patients. PATIENTS AND METHODS: In this cohort study (NCT02269878), 68 epithelioid MPM Egyptian patients treated with first-line platinum-based chemotherapy were recruited in the period between April 2014 and May 2015...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27845436/profiling-ribonucleotide-and-deoxyribonucleotide-pools-perturbed-by-gemcitabine-in-human-non-small-cell-lung-cancer-cells
#8
Jian-Ru Guo, Qian-Qian Chen, Christopher Wai Kei Lam, Cai-Yun Wang, Vincent Kam Wai Wong, Zee-Fen Chang, Wei Zhang
In this study, we investigated the dosage effect of gemcitabine, an inhibitor of ribonucleotide reductase (RR), on cellular levels of ribonucleotides and deoxyribonucleotides using high performance liquid chromatography-electrospray ionization tandem mass spectrometric method. As anticipated, after 4-h incubation of non-small cell lung cancer (A549) cells with gemcitabine at 0.5 and 2 μM, there were consistent reductions in levels of deoxyribonucleoside diphosphates (dNDP) and their corresponding deoxyribonucleoside triphosphates (dNTP)...
November 15, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27825639/drug-dose-per-kilogram-lean-body-mass-predicts-hematologic-toxicity-from-carboplatin-doublet-chemotherapy-in-advanced-non-small-cell-lung-cancer
#9
Bjørg Sjøblom, Jūratė Šaltytė Benth, Bjørn H Grønberg, Vickie E Baracos, Michael B Sawyer, Øystein Fløtten, Marianne J Hjermstad, Nina Aass, Marit Jordhøy
BACKGROUND: Variations in lean body mass (LBM) have been suggested to explain variations in toxicity from systemic cancer treatment. We investigated if drug doses per kilogram of LBM were associated with severe hematologic toxicity (HT) in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) enrolled onto randomized trials comparing first-line carboplatin-doublets. PATIENTS AND METHODS: Patients received carboplatin (AUC [area under the plasma concentration vs...
October 5, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27797249/impact-of-the-copper-transporter-protein-1-ctr1-polymorphism-on-adverse-events-among-advanced-nonsmall-cell-lung-cancer-patients-treated-with-a-carboplatin-gemcitabine-regimen
#10
Siriluk Kumpiro, Virote Sriuranpong, Nutthada Areepium
BACKGROUND: Platinum-based regimens are effective treatments for advanced non-small cell lung cancer (NSCLC), but the five-year survival rate is still less than 20%. One possible factor appears to be resistance involving polymorphisms in the CTR1 gene which plays an importance role in accumulation of platinum in the cytoplasm. PURPOSE: To establish both prevalence of CTR1 polymorphism and its impact on treatment related toxicity in Thai advanced NSCLC patients. MATERIALS AND METHODS: Thirty-two advanced NSCLC participants received carboplatin and gemcitabine during January to June 2016 at King Chulalongkorn Memorial Hospital (KCMH) were recruited for analysis of the CTR1 rs12686377 genotype...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27765756/safety-and-efficacy-of-nivolumab-and-standard-chemotherapy-drug-combination-in-patients-with-advanced-non-small-cell-lung-cancer-a-four-arms-phase-ib-study
#11
S Kanda, K Goto, H Shiraishi, E Kubo, A Tanaka, H Utsumi, K Sunami, S Kitazono, H Mizugaki, H Horinouchi, Y Fujiwara, H Nokihara, N Yamamoto, H Hozumi, T Tamura
BACKGROUND: The human IgG4 monoclonal antibody nivolumab targets programmed cell death-1 (PD-1) and promotes antitumor response by blocking the interaction of PD-1 with its ligands. This single-center phase Ib study investigated the tolerability, safety, and pharmacokinetics of nivolumab combined with standard chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients who had stage IIIB without indication for definitive radiotherapy, stage IV, or recurrent NSCLC were eligible...
October 20, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27737534/ercc1-expression-based-randomized-phase-ii-study-of-gemcitabine-cisplatin-versus-irinotecan-cisplatin-in-patients-with-advanced-non-small-cell-lung-cancer
#12
Ji-Youn Han, Geon Kook Lee, Kun Young Lim, Young Ju Lee, Byung Ho Nam, Jin Soo Lee
Purpose: We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Materials and Methods: Eligible patients were randomly assigned to the GP (gemcitabine 1,250 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1 every 3 weeks) or IP (irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 every 3 weeks) arm. The primary goal of this study was to compare the response rate (RR) of the GP and IP arms according to the ERCC1 expression level...
October 11, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27695347/clinical-comparative-investigation-of-efficacy-and-toxicity-of-cisplatin-plus-gemcitabine-or-plus-abraxane-as-first-line-chemotherapy-for-stage-iii-iv-non-small-cell-lung-cancer
#13
Dan Ai, Yan Guan, Xiu-Ju Liu, Chu-Feng Zhang, Peng Wang, Hong-Lu Liang, Qi-Sen Guo
PURPOSE: The purpose of this study was to observe the clinical efficacy and toxicity of cisplatin in combination with gemcitabine or Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 200 patients with advanced NSCLC, which was confirmed by pathology or cytology, were enrolled into our research by reviewing previous complete and retrievable medical records data of our hospital. A total of 100 patients were treated with gemcitabine (1,000 mg/m(2), day 1 and day 8) in combination with cisplatin (75 mg/m(2), days 1-3; GP group) and another 100 patients were treated with Abraxane (260 mg/m(2), day 1) in combination with cisplatin (75 mg/m(2), days 1-3; TP group)...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27646667/-lung-adenocarcinoma-with-concomitant-egfr-mutation-and-alk-rearrangement
#14
J Caliez, I Monnet, A Pujals, G Rousseau-Bussac, L Jabot, A Boudjemaa, K Leroy, C Chouaid
INTRODUCTION: Among patients with non-small-cell lung cancer, coexistence of EGFR mutation and ALK rearrangement is rare. We describe the clinical features of two patients with this double anomaly. CASE REPORTS: A 62-year-old Caucasian non-smoking woman was diagnosed with cT4N0M0 lung adenocarcinoma. Initial biopsy showed EGFR mutation and ALK rearrangement. She received cisplatin-gemcitabine, followed by 17 months of gemcitabine. Owing to progression, she received erlotinib for 14 months, then paclitaxel for 6 months and finally crizotinib...
September 16, 2016: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/27623620/repeated-iodine-125-seed-implantations-combined-with-external-beam-radiotherapy-for-the-treatment-of-locally-recurrent-or-metastatic-stage-iii-iv-non-small-cell-lung-cancer-a-retrospective-study
#15
Wei Li, Gang Dan, Jianqing Jiang, Yifeng Zheng, Xiushan Zheng, Dan Deng
BACKGROUND: Recurrent or metastatic lung cancer is difficult to manage. This retrospective study aimed to assess the efficacy of repeated iodine-125 seed implantations combined with external beam radiotherapy (EBRT) for locally recurrent or metastatic stage-III/IV non-small cell lung cancer (NSCLC). METHODS: Eighteen previously treated stage-III/IV NSCLC patients with local or metastatic recurrences underwent 1-to-3 iodine-125 implantations. Six of these patients received palliative EBRT and six patients received combined chemotherapy using gemcitabine and cisplatin...
2016: Radiation Oncology
https://www.readbyqxmd.com/read/27621656/clinical-potential-of-necitumumab-in-non-small-cell-lung-carcinoma
#16
REVIEW
Carlo Genova, Fred R Hirsch
Despite significant progress, new therapeutic approaches for advanced non-small cell lung cancer (NSCLC) are highly needed, particularly for the treatment of patients with squamous cell carcinoma. The epidermal growth factor receptor (EGFR) is often overexpressed in NSCLC and represents a relevant target for specific treatments. Although EGFR mutations are more frequent in non-squamous histology, the receptor itself is more often overexpressed in squamous NSCLC. Necitumumab is a human monoclonal antibody that is able to inhibit the EGFR pathway and cause antibody-dependent cell cytotoxicity...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27617917/clinical-observation-of-docetaxel-or-gemcitabine-combined-with-cisplatin-in-the-chemotherapy-after-surgery-for-stage-ii-iii-non-small-cell-lung-cancer
#17
Q Chen, X Ji, X Zhou, Q Shi, H Yu, H Fu
Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of non-small cell lung cancer (NSCLC). Methods: A total of 92 patients diagnosed with NSCLC after surgery were enrolled, and they were treated with DP (DP group) and GP (GP group). The efficacy and toxicity of the medications were then compared. Results: Approximately 92...
November 18, 2015: West Indian Medical Journal
https://www.readbyqxmd.com/read/27614872/necitumumab-plus-gemcitabine-and-cisplatin-as-first-line-therapy-in-patients-with-stage-iv-egfr-expressing-squamous-non-small-cell-lung-cancer-german-subgroup-data-from-an-open-label-randomized-controlled-phase-3-study-squire
#18
Martin Reck, Michael Thomas, Cornelia Kropf-Sanchen, Jörg Mezger, Mark A Socinski, Henrik Depenbrock, Victoria Soldatenkova, Jacqueline Brown, Thomas Krause, Nick Thatcher
BACKGROUND: In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. We explored data for the German subpopulation (N = 96) of SQUIRE patients with EGFR-expressing tumors. PATIENT AND METHODS: Patients with stage IV sqNSCLC were randomized 1:1 to up to 6 cycles of open-label GC + N or GC alone...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27598338/phase-i-study-of-chk1-inhibitor-ly2603618-in-combination-with-gemcitabine-in-patients-with-solid-tumors
#19
Emiliano Calvo, Fadi Braiteh, Daniel Von Hoff, Robert McWilliams, Carlos Becerra, Matthew D Galsky, Gayle Jameson, Ji Lin, Scott McKane, Enaksha R Wickremsinhe, Scott M Hynes, Aimee Bence Lin, Karla Hurt, Donald Richards
OBJECTIVE: LY2603618, a selective inhibitor of checkpoint kinase 1 (CHK1) and key regulator of the DNA damage checkpoint, may enhance the effects of antimetabolites. This phase I study defined the recommended phase II dose of LY2603618 combined with gemcitabine. PATIENTS AND METHODS: Patients with advanced/metastatic disease were administered doses of LY2603618 (70-250 mg/m2 or flat-fixed doses of 200 or 230 mg) after gemcitabine (1,000 mg/m2). Safety and pharmacokinetics (PK) were assessed...
September 7, 2016: Oncology
https://www.readbyqxmd.com/read/27535394/targeted-therapies-for-lung-cancer
#20
Thomas E Stinchcombe
Targeted therapies have become standard therapies for patients with non-small cell lung cancer (NSCLC). A phase III trial of carboplatin and paclitaxel with and without bevacizumab in patients with advanced NSCLC with non-squamous histology demonstrated a statistically significant improvement in efficacy. In patients with NSCLC with an activating epidermal growth factor receptor (EGFR) mutation (defined as exon 19 deletion and exon 21 L858R point mutation), phase III trials of EGFR tyrosine kinase inhibitors (TKI) compared to platinum-based chemotherapy have demonstrated superior efficacy in the first-line setting...
2016: Cancer Treatment and Research
keyword
keyword
43169
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"